Finally, the AMPLITUDE-O trial, which included patients with T2D and either a history of CVD (90%) or CKD, demonstrated that efpeglenatide significantly reduced MACE by 27% (HR 0.73; p ##### 0.001), confirming the class effect even with agents structurally distinct from native GLP-1 (25). This evidence concerns the gene GCG and type 2 diabetes mellitus.